Figure 7.

(A) Blood clearance of ¹¹¹In-labelled PC3 (prostate cancer) and MCF-7 (breast cancer) sEVs, compared to liposomes. (B) Ex vivo biodistribution of ¹¹¹In-labelled PC3 sEVs in PC3 tumor-bearing nude mice and non-tumor bearing mice 24 h post injection. Figures taken with permission from Smyth et al. ⁸⁵ (C) In vivo biodistribution of iv. administered [¹¹¹In]In-oxinate labelled CD206-positive M2 macrophage targeting sEVs (middle image) as well as control groups (left and right images) in tumour bearing BALB/c mice at 3 h post injection. Figure taken with permission from Rashid et al. ⁸⁶ (D) Ex vivo biodistribution of iv. administered [¹¹¹In]In-tropolone and [¹¹¹In]In-DTPA labelled B16-F10 sEVs at 24 h post injection. Data presented as mean ± SD of n = 3 and analysed by Student's t-test. Figure adapted with permission from Faruqu et al. ⁸⁴.